Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Dec 11 (Reuters) - Eli Lilly said on Thursday its ‌next-generation ​obesity drug helped patients lose ‌an average of 28.7% of ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...

Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. President Trump said he has decided on who he plans to nominate to replace ...

With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

While the WHO study saw reports of suicidal thoughts were slightly higher for semaglutide in particular, the warning applies for all GLP-1s, including Saxenda, Trulicity and Mounjaro. Semaglutide is ...

Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.